Shares Magazine
24.50p-1.00 (-3.92%)26 Apr 2024, 17:06
Jump to:
Renalytix PLC Fundamentals
| Company Name | Renalytix PLC | Last Updated | 2024-04-26 |
|---|---|---|---|
| Industry | Health Information Services | Sector | Healthcare |
| Shares in Issue | 127.552 m | Market Cap | £31.25 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.55 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.3882 | Debt Equity Ratio | 1.9910 |
| Asset Equity Ratio | 8.2017 | Cash Equity Ratio | 2.5643 |
| Quick Ratio | 0.5907 | Current Ratio | 0.68 |
| Price To Book Value | 14.6628 | ROCE | 0 |
Renalytix PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Renalytix PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $1.19 m | $1.37 m | $2.46 m |
| Intangible Assets | 0 | 0 | $18.02 m |
| Investments | $1.46 m | $2.75 m | 0 |
| Total Fixed Assets | $3.75 m | $5.31 m | $26.57 m |
| Stocks | 0 | 0 | $353,000.00 |
| Debtors | $776,000.00 | $976,000.00 | $594,000.00 |
| Cash & Equivalents | $24.68 m | $41.33 m | $74.45 m |
| Other Assets | 0 | 0 | $6.09 m |
| Total Assets | $30.63 m | $50.06 m | $102.58 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $16.14 m | $11.78 m | $7.26 m |
| Creditors after 1 year | $7.53 m | $7.68 m | $213,000.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $23.66 m | $19.46 m | $7.48 m |
| Net assets | $6.97 m | $30.61 m | $95.10 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $286,000.00 | $228,000.00 | $233,000.00 |
| Share Premium | $186.46 m | $164.01 m | $76.46 m |
| Profit / Loss | -$45.60 m | -$45.25 m | -$35.79 m |
| Other Equity | $6.97 m | $30.61 m | $95.10 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $6.97 m | $30.61 m | $95.10 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.52 | $0.20 | $0.00 |
| Debt-to-Equity | $1.08 | $0.25 | $0.00 |
| Assets / Equity | 8.2017 | 8.2017 | 8.2017 |
| Cash / Equity | 2.5643 | 2.5643 | 2.5643 |
| EPS | -$0.50 | -$0.60 | -$0.51 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -$34.09 m | -$45.92 m | -$24.63 m |
| Cashflow before financing | -$17.70 m | -$20.29 m | $52.61 m |
| Increase in Cash | -$16.65 m | -$23.80 m | $51.87 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $3.40 m | $2.97 m | $1.49 m |
| Cost of sales | $2.68 m | $2.10 m | $804,000.00 |
| Gross Profit | $720,000.00 | $874,000.00 | $687,000.00 |
| Operating Profit | -$42.22 m | -$53.18 m | -$32.61 m |
| Pre-Tax profit | -$45.60 m | -$45.25 m | -$35.79 m |
Renalytix PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. |
| Latest Interim Date | 15 Feb 2024 |
| Latest Fiscal Year End Date | 28 Sep 2023 |
Renalytix PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2022-04-07 | Ms. Ann E. Berman | Independent Director |
| 2023-11-22 | Mr. Howard B. Doran, Jr. | Chief Business Officer |
| 2023-07-11 | Mr. Thomas H. Mclain | President |
| 2023-10-24 | Mr. Timothy John Scannell | Independent Director |
| 2024-03-14 | Mr. Daniel Joseph Levangie | Non-Executive Director |
| 2024-03-18 | Mr. Christopher Harwood Bernard Mills | Non-Executive Director |
| 2020-07-17 | Mr. Julian Baines | Non-Executive Director,Chairman |
| 2020-07-17 | Mr. Richard Anthony Evans | Non-Executive Director |
| 2024-03-14 | Mr. James Renwick McCullough | Executive Director,Chief Executive Officer |
| 2024-03-14 | Mr. Fergus Fleming | Executive Director,Chief Technical Officer |
| 2021-07-01 | Dr. Barbara Murphy | Independent Director |
| 2023-07-03 | Dr. Erik Lium, PhD | Director |
| 2024-03-08 | Mr. O. James Sterling | Chief Financial Officer and Principal Accounting Officer |
| 2023-12-08 | Dr. Chirag Rohit Parikh, M.D.,PhD | Independent Director |
| 2023-07-07 | Dr. Michael J. Donovan, M.D.,PhD | Chief Medical Officer |
| 2024-03-14 | Ms. Catherine Havlik Coste | Non-Executive Director,Chairman |
Renalytix PLC Contact Details
| Company Name | Renalytix PLC |
|---|---|
| Address | 19 Stanwell Road, Avon House, Cardiff, CF64 2EZ |
| Telephone | |
| Website | https://www.renalytix.com |
Renalytix PLC Advisors
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Darktrace PLC | 602.00 | 16.44 |
| Travis Perkins PLC | 766.00 | 6.46 |
| Natwest Group PLC | 307.40 | 6.07 |
| Ashtead Group PLC | 6,104.00 | 5.97 |
| Tritax Eurobox PLC | 53.80 | 4.87 |
| Tbc Bank Group PLC | 3,450.00 | 4.39 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Convatec Group PLC | 257.80 | -6.46 |
| Wh Smith PLC | 1,120.00 | -5.25 |
| Beazley PLC | 638.00 | -3.11 |
| Entain PLC | 784.20 | -3.09 |
| Me Group International PLC | 162.80 | -2.75 |
| Ocado Group PLC | 353.10 | -2.54 |
Risers/fallers data from previous trading day.